AI
Friday, June 20, 2025 1:17:21 PM
You have been bullshitting a lot, which only corroborate you are a fake Ph.D.
See this collaboration trial between Merck and NWBO on colorectal cancer. Had they published any results on the trial, could Merck have acquired Immune Design for $300m for its TLR4?
https://www.rlp-forschung.de/public/facilities/2771/research_projects/22146
Instead of posting nonsense all the time, you need to read all the publications on DCVax-L and do an extensive literature review. You didn't receive training like this when you studied for your fake Ph.D., did you?
For DCVax-L, the most important part is not about OS or PFS even though these are important measures. The most important part is whether it can trigger massive and sustainable t-cell infiltration into tumor sites of all types of solid tumors. Then all these inhibitors that only work in presence of t-cells will improve the efficacy. Do you get it now?
What is the occurrence rate of pseudoprogresson in the p3 trial? It is over 30%. I am talking about DCVa-L alone case. With the addition of poly-iclc, the rate should be much higher. See the following figure? Pseudoprogression correlates with significant OS, which is obvious.
It's no surprise a fake Ph.D. has no seminal understanding about the publications. Not to mention to have vision.
See this collaboration trial between Merck and NWBO on colorectal cancer. Had they published any results on the trial, could Merck have acquired Immune Design for $300m for its TLR4?
https://www.rlp-forschung.de/public/facilities/2771/research_projects/22146
Instead of posting nonsense all the time, you need to read all the publications on DCVax-L and do an extensive literature review. You didn't receive training like this when you studied for your fake Ph.D., did you?
For DCVax-L, the most important part is not about OS or PFS even though these are important measures. The most important part is whether it can trigger massive and sustainable t-cell infiltration into tumor sites of all types of solid tumors. Then all these inhibitors that only work in presence of t-cells will improve the efficacy. Do you get it now?
What is the occurrence rate of pseudoprogresson in the p3 trial? It is over 30%. I am talking about DCVa-L alone case. With the addition of poly-iclc, the rate should be much higher. See the following figure? Pseudoprogression correlates with significant OS, which is obvious.
It's no surprise a fake Ph.D. has no seminal understanding about the publications. Not to mention to have vision.
